Vaccination Offers Partial Protection for Postacute Phase of COVID-19
Vaccination against SARS-CoV-2 offers partial protection in the postacute phase of the disease.
Vaccination against SARS-CoV-2 offers partial protection in the postacute phase of the disease.
Researchers assessed patients who developed a new-onset neuromuscular disorder the first 6 weeks after receiving either the first or second dose of the COVID-19 vaccine.
Researchers sought to assess the incidence of Guillain-Barré syndrome following vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines.
The Pfizer-BioNTech COVID-19 vaccine contributed to substantial public health impact and vaccine-preventable cost savings in the first year of its US rollout.
A single booster dose of the Pfizer COVID-19 vaccine can be given to 5- to 11-year-olds.
Coronavirus-like particles, which are produced in plants, combined with an adjuvant forms a vaccine that is effective for preventing COVID-19.
Pfizer Inc announced it has asked the FDA to approve emergency use of its booster shot for children ages 5 to 11 years.
The risk for myocarditis and pericarditis after COVID-19 mRNA vaccines is highest in young men after the second vaccine dose.
Unvaccinated individuals with prior symptomatic COVID-19 have a much lower risk for acquiring recurrent COVID-19 than unvaccinated individuals without prior COVID-19 for up to 9 months from the index infection
Higher vaccination coverage is associated with lower rates of COVID-19 mortality and incidence in the United States.